Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
NeuroOne Medical Technologies ( (NMTC) ) has provided an update.
On December 21, 2022, NeuroOne Medical Technologies Corporation entered into a Capital on Demand™ Sales Agreement with JonesTrading Institutional Services LLC, allowing the company to sell shares of its common stock through an ‘at the market offering.’ On August 15, 2025, the company filed an updated Prospectus Supplement for the sale of up to $6.75 million of shares, potentially impacting its financial strategy and market presence.
The most recent analyst rating on (NMTC) stock is a Buy with a $1.45 price target. To see the full list of analyst forecasts on NeuroOne Medical Technologies stock, see the NMTC Stock Forecast page.
Spark’s Take on NMTC Stock
According to Spark, TipRanks’ AI Analyst, NMTC is a Neutral.
NeuroOne Medical Technologies shows strong revenue growth and promising corporate developments, but profitability challenges and valuation concerns weigh on the score. The company’s stable financial position and strategic initiatives provide a foundation for potential future growth.
To see Spark’s full report on NMTC stock, click here.
More about NeuroOne Medical Technologies
NeuroOne Medical Technologies Corporation operates in the medical technology industry, focusing on the development and commercialization of thin-film electrode technology for neurological applications.
Average Trading Volume: 199,021
Technical Sentiment Signal: Sell
Current Market Cap: $41.35M
See more data about NMTC stock on TipRanks’ Stock Analysis page.